Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c1801 |
|---|---|
| Identifier | NCT05913817 |
| Trial Title | The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications. |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn Disease|Ulcerative Colitis|Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Plaque Psoriasis|Hidradenitis Suppurativa |
| Interventions | BIOLOGICAL: AVT02 (Alvotech Biosimilar to Adalimumab) |
Participant Information
| Sponsor | Jamp Pharma Corporation |
|---|---|
| City | Montréal |
| Country/Region | Canada |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | OBSERVATIONAL |
|---|---|
| Phase | - |
Time Information
| Start Date | 2023-01-09 |
|---|---|
| Primary Completion Date | 2024-12-18 |
| Completion Date | 2025-05-13 |